专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2009099830A3 EDIBLE FILM-STRIPS FOR IMMEDIATE RELEASE OF ACTIVE INGREDIENTS 审中-公开
标题翻译：可食用薄膜立即释放活性成分
公开(公告)号：WO2009099830A3
公开(公告)日：2011-01-20
申请号：PCT/US2009032228
申请日：2009-01-28
申请人： MCNEIL PPC INC , BUNICK FRANK J , WYNN DAVID W , LEE DER-YANG
发明人： BUNICK FRANK J , WYNN DAVID W , LEE DER-YANG
IPC分类号： A61K9/70 , A61K47/48
CPC分类号： A61K9/0056 , A61K9/7007 , A61K47/585
摘要： The present invention is directed to an edible film that contains two or more segmented portions and comprises an active ingredient that is distributed on a segmented portion or portions which comprise less than 50% of the cross sectional surface area of a major face of said film. The present invention also relates to methods of treatment for the treatment of various conditions and for taste-masking of pharmaceutical ingredients.
摘要翻译：本发明涉及一种包含两个或更多个分段部分并且包含分布在分段部分上的活性成分的可食性薄膜或包含小于所述薄膜主面的横截面积的50％的部分。本发明还涉及用于治疗各种病症和药物成分掩味的治疗方法。

2. 发明申请

WO2009023030A8 IMMEDIATE RELEASE AND SUSTAINED RELEASE IBUPROFEN DOSING REGIMEN 审中-公开
标题翻译：立即发布和持续发布IBUPROFEN剂量计划
公开(公告)号：WO2009023030A8
公开(公告)日：2010-11-25
申请号：PCT/US2007075990
申请日：2007-08-15
申请人： MCNEIL PPC INC , LEE DER-YANG , BUNICK FRANK , SCHWING JAMES
发明人： LEE DER-YANG , BUNICK FRANK , SCHWING JAMES
IPC分类号： A61K9/20 , A61K9/28 , A61K31/19 , A61P29/00
CPC分类号： A61K31/19 , A61K9/2086 , A61K9/209 , A61K9/2095 , A61K9/2866 , A61K9/2873 , A61K9/2886 , A61K9/2893 , A61K31/192
摘要： A method of administering non-steroidal-anti-inflammatory drugs, in particular propionic acid derivatives such as ibuprofen, is provided. The inventive dosage forms provide an initial release of the NSAID and a second sustained release of NSAID, preferably in a single dosing step.
摘要翻译：提供给予非甾体抗炎药物，特别是丙酸衍生物如布洛芬的方法。本发明的剂型提供NSAID的初始释放和NSAID的第二次缓释，优选在单个给药步骤中。

3. 发明申请

WO2008064192A3 MODIFIED RELEASE ANALGESIC SUSPENSIONS 审中-公开
标题翻译：改良释放止血药
公开(公告)号：WO2008064192A3
公开(公告)日：2008-09-04
申请号：PCT/US2007085166
申请日：2007-11-20
申请人： MCNEIL PPC INC , LEE DER-YANG , CHEN JEN-CHI , CHEN VINCENT , SHEN ROBERT
发明人： LEE DER-YANG , CHEN JEN-CHI , CHEN VINCENT , SHEN ROBERT
IPC分类号： A61K9/10
CPC分类号： A61K9/5084 , A61K9/0095 , A61K9/5026 , A61K9/5047 , A61K9/5073 , A61K31/137 , A61K31/192 , A61K45/06 , A61K47/585 , A61K2300/00
摘要： A pharmaceutical dosage form comprising non-steroidal-anti-inflammatory drugs, in particular propionic acid derivatives such as ibuprofen, along with a second active ingredient having a shorter therapeutically effective plasma concentration duration, such as phenylephrine, and methods of administering the same are provided. This method provides improved therapeutic effect, in particular pain relief along with decongestant relief, over extended time periods.
摘要翻译：提供包含非甾体抗炎药物，特别是丙酸衍生物如布洛芬的药物剂型，以及具有较短治疗有效血浆浓度持续时间的第二活性成分，例如去氧肾上腺素及其施用方法。该方法在延长的时间段内提供改善的治疗效果，特别是与减充血剂缓解一起的疼痛缓解。

4. 发明申请

WO03026626A3 MODIFIED RELEASE DOSAGE FORMS 审中-公开
标题翻译：修改释放剂量形式
公开(公告)号：WO03026626A3
公开(公告)日：2003-10-16
申请号：PCT/US0231062
申请日：2002-09-28
申请人： MCNEIL PPC INC , LEE DER-YANG , LI SHUN-POR , PARIKH NARENDRA , SOWDEN HARRY S , THOMAS MARTIN , WYNN DAVID
发明人： LEE DER-YANG , LI SHUN-POR , PARIKH NARENDRA , SOWDEN HARRY S , THOMAS MARTIN , WYNN DAVID
IPC分类号： A23G3/34 , A23G1/00 , A23G1/54 , A23G3/00 , A23G3/04 , A23G3/36 , A23G3/54 , A23L1/00 , A23L1/09 , A23L1/30 , A61J3/00 , A61J3/06 , A61J3/10 , A61K9/00 , A61K9/14 , A61K9/20 , A61K9/22 , A61K9/24 , A61K9/26 , A61K9/28 , A61K9/30 , A61K9/32 , A61K9/34 , A61K9/36 , A61K9/38 , A61K9/48 , A61K9/50 , A61K31/136 , A61K31/137 , A61K31/277 , A61K47/10 , A61K47/14 , A61K47/26 , A61K47/30 , A61K47/32 , A61K47/34 , A61K47/36 , A61K47/38 , A61K47/44 , A61K47/46 , A61P11/00 , B30B11/08 , B30B11/34 , B30B15/30 , G06F17/30
CPC分类号： A23G3/04 , A23G1/54 , A23G3/0029 , A23G3/368 , A23G3/54 , A23L29/30 , A61J3/005 , A61J3/06 , A61J3/10 , A61K9/0004 , A61K9/0056 , A61K9/2013 , A61K9/2018 , A61K9/2027 , A61K9/2031 , A61K9/2054 , A61K9/2068 , A61K9/2072 , A61K9/2081 , A61K9/209 , A61K9/2095 , A61K9/282 , A61K9/2826 , A61K9/284 , A61K9/286 , A61K9/2873 , A61K9/2886 , A61K9/2893 , A61K9/5084 , B30B11/08 , B30B11/34 , B30B15/302 , Y10T428/1352
摘要： A dosage form comprises: (a) a core comprising at least one active ingredient; and (b) a molded shell which surrounds the core, wherein the shell provides a predetermined time delay of greater than one hour for the onset of dissolution of the active ingredient upon contacting of the dosage form with a liquid medium and the delay is independent of the pH of the liquid medium. The weight of the shell may be at least 50 percent of the weight of the core, and the shell may have a thickness of about 500-4000 microns, or be substantially free of pores having a diameter of 0.5 to 5 microns.
摘要翻译：剂型包含：（a）包含至少一种活性成分的核心; 和（b）围绕核心的模制外壳，其中该外壳提供大于一小时的预定时间延迟，用于活性成分在剂型与液体介质接触时开始溶解，延迟独立于液体介质的pH值。壳的重量可以是芯的重量的至少50％，并且壳可以具有约500-4000微米的厚度，或者基本上不具有直径为0.5-5微米的孔。

5. 发明申请

WO03026628A3 COMPOSITE DOSAGE FORMS HAVING AN INLAID PORTION 审中-公开
标题翻译：具有嵌入部分的复合剂型
公开(公告)号：WO03026628A3
公开(公告)日：2003-05-01
申请号：PCT/US0231063
申请日：2002-09-28
申请人： MCNEIL PPC INC , LEE DER-YANG , SOWDEN HARRY S , THOMAS MARTIN
发明人： LEE DER-YANG , SOWDEN HARRY S , THOMAS MARTIN
IPC分类号： A23G3/34 , A23G1/00 , A23G1/54 , A23G3/00 , A23G3/04 , A23G3/36 , A23G3/54 , A23L1/00 , A23L1/09 , A23L1/30 , A61J3/00 , A61J3/06 , A61J3/10 , A61K9/00 , A61K9/14 , A61K9/20 , A61K9/22 , A61K9/24 , A61K9/26 , A61K9/28 , A61K9/30 , A61K9/32 , A61K9/34 , A61K9/36 , A61K9/38 , A61K9/48 , A61K9/50 , A61K31/136 , A61K31/137 , A61K31/277 , A61K47/10 , A61K47/14 , A61K47/26 , A61K47/30 , A61K47/32 , A61K47/34 , A61K47/36 , A61K47/38 , A61K47/44 , A61K47/46 , A61P11/00 , B30B11/08 , B30B11/34 , B30B15/30 , G06F17/30
CPC分类号： A23G3/04 , A23G1/54 , A23G3/0029 , A23G3/368 , A23G3/54 , A23L29/30 , A61J3/005 , A61J3/06 , A61J3/10 , A61K9/0004 , A61K9/0056 , A61K9/2013 , A61K9/2018 , A61K9/2027 , A61K9/2031 , A61K9/2054 , A61K9/2068 , A61K9/2072 , A61K9/2081 , A61K9/209 , A61K9/2095 , A61K9/282 , A61K9/2826 , A61K9/284 , A61K9/286 , A61K9/2873 , A61K9/2886 , A61K9/2893 , A61K9/5084 , B30B11/08 , B30B11/34 , B30B15/302 , Y10T428/1352
摘要： A dosage form comprises at least one active ingredient, a first portion which comprises an exterior surface and one or more cavities defining at least one interior surface having indentations and an exterior surface, and a second molded portion which is inlaid into the cavities of the first portion and has an exterior surface. The first and second portions are in contact at an interface, the second portion comprises a solidified thermoplastic material, and the second portion resides substantially conformally upon the indentations of the first portion. In another embodiment, a dosage form comprises at least one active ingredient, a core having an outer surface and a shell residing on at least a portion of the core outer surface, wherein the shell comprises a first shell portion and a second molded shell portion which is inlaid into the first shell portion. In another embodiment, a dosage form comprises at least one active ingredient, a core, and a shell having a first molded shell portion which is discontinuous, and a second molded shell portion which is continuous, such that the discontinuities of the first shell portion are due to the presence of the second molded shell portion, and the first and second shell portions are compositionally different.
摘要翻译：剂型包含至少一种活性成分，第一部分和第二部分，所述第一部分包含外表面和限定至少一个内表面的一个或多个空腔，所述内表面具有压痕和外表面，所述第二模塑部分嵌入第一部分并具有外表面。第一部分和第二部分在界面处接触，第二部分包括固化的热塑性材料，并且第二部分基本共形地位于第一部分的凹陷上。在另一个实施方案中，剂型包含至少一种活性成分，具有外表面的核心和驻留在核心外表面的至少一部分上的壳，其中壳包含第一壳部分和第二模壳部分，嵌入第一壳部分。在另一个实施方案中，剂型包含至少一种活性成分，核心和具有不连续的第一模制壳部分和第二模制壳部分的壳，所述第二模制壳部分是连续的，使得第一壳部分的不连续部分是由于第二模制壳部分的存在，并且第一壳部分和第二壳部分在组成上不同。

6. 发明申请

WO2003026624A1 MODIFIED RELEASE DOSAGE FORMS 审中-公开
标题翻译：修改释放剂量表
公开(公告)号：WO2003026624A1
公开(公告)日：2003-04-03
申请号：PCT/US2002/031022
申请日：2002-09-28
申请人： MCNEIL-PPC, INC. , LEE, Der-Yang , LI, Shun-Por , SOWDEN, Henry, S. , THOMAS, Martin , WYNN, David
发明人： LEE, Der-Yang , LI, Shun-Por , SOWDEN, Henry, S. , THOMAS, Martin , WYNN, David
IPC分类号： A61K9/20
CPC分类号： A23G3/04 , A23G1/54 , A23G3/0029 , A23G3/368 , A23G3/54 , A23L29/30 , A61J3/005 , A61J3/06 , A61J3/10 , A61K9/0004 , A61K9/0056 , A61K9/2013 , A61K9/2018 , A61K9/2027 , A61K9/2031 , A61K9/2054 , A61K9/2068 , A61K9/2072 , A61K9/2081 , A61K9/209 , A61K9/2095 , A61K9/282 , A61K9/2826 , A61K9/284 , A61K9/286 , A61K9/2873 , A61K9/2886 , A61K9/2893 , A61K9/5084 , B30B11/08 , B30B11/34 , B30B15/302 , Y10T428/1352
摘要： In one embodiment a dosage form comprises at least one active ingredient and a molded matrix which comprises from 10 to 100% of a material having a melting point of less than about 100 degrees C selected from the stamp consisting of thermoplastic polyalkylene oxides, low melting hydrophobic materials, thermoplastic polymers, thermoplastic starches and combinations thereof, and the matrix is capable of providing modified release of the active ingredient upon contacting of the dosage form with a liquid medium. The dosage form may additionally comprise uncoated particles which may contain at least one active ingredient. In another embodiment, a dosage form comprises at least one active ingredient, a plurality of particles and a molded matrix, wherein at least a portion of the particles are coated. The coated particles, the matrix or both may comprise at least one active ingredient, and the coated particles or the matrix or a combination thereof is capable of providing modified release of the active ingredient upon contacting of the dosage form with a liquid medium.
摘要翻译：在一个实施方案中，剂型包含至少一种活性成分和模塑基质，其包含10〜100％的熔点小于约100℃的材料，所述材料选自热塑性聚环氧烷，低熔点疏水性材料，热塑性聚合物，热塑性淀粉及其组合，并且所述基质能够在剂型与液体介质接触时提供活性成分的改性释放。剂型还可以包含可以含有至少一种活性成分的未涂覆的颗粒。在另一个实施方案中，剂型包含至少一种活性成分，多个颗粒和模制基质，其中至少一部分颗粒被涂覆。涂覆的颗粒，基质或两者可以包含至少一种活性成分，并且涂覆的颗粒或基质或其组合能够在剂型与液体介质接触时提供活性成分的改性释放。

7. 发明申请

WO2003026612A2 DOSAGE FORMS HAVING AN INNER CORE AND OUTER SHELL 审中-公开
标题翻译：具有内核和外壳的剂型
公开(公告)号：WO2003026612A2
公开(公告)日：2003-04-03
申请号：PCT/US2002/031066
申请日：2002-09-28
申请人： MCNEIL-PPC, INC. , BUNICK, Frank, J. , SOWDEN, Harry, S. , THOMAS, Martin , BURKE, John , LEE, Der-Yang
发明人： BUNICK, Frank, J. , SOWDEN, Harry, S. , THOMAS, Martin , BURKE, John , LEE, Der-Yang
IPC分类号： A61K9/00
CPC分类号： A23G3/04 , A23G1/54 , A23G3/0029 , A23G3/368 , A23G3/54 , A23L29/30 , A61J3/005 , A61J3/06 , A61J3/10 , A61K9/0004 , A61K9/0056 , A61K9/2013 , A61K9/2018 , A61K9/2027 , A61K9/2031 , A61K9/2054 , A61K9/2068 , A61K9/2072 , A61K9/2081 , A61K9/209 , A61K9/2095 , A61K9/282 , A61K9/2826 , A61K9/284 , A61K9/286 , A61K9/2873 , A61K9/2886 , A61K9/2893 , A61K9/5084 , B30B11/08 , B30B11/34 , B30B15/302 , Y10T428/1352
摘要： In one embodiment, the dosage form of this invention comprises a core having an outer surface and a shell having outer and inner surfaces, wherein the shell surrounds the core such that the shell inner surface resides substantially conformally upon the core outer surface, the shell thickness is in the range of about 100-400 microns, the relative standard deviation of the shell thickness on the dosage form is less than about 30 %, the shell comprises less than about 50 % crystallizable sugar, and the dosage form is substantially free of charge control agents. In another embodiment, the dosage form comprises a core having an outer surface and a shell having outer and inner surfaces, wherein the shell surrounds the core, the dosage form moisture uptake at 60 minutes exposure to 40 °C and 75 % relative humidity is less than about 0.80 %, the shell thickness is in the range of about 100-400 microns, the relative standard deviation of the shell thickness on the dosage form is less than about 30 %, the dosage form is substantially free of charge control agents and the shell is substantially free of a raised seam.
摘要翻译：在一个实施方案中，本发明的剂型包括具有外表面和具有外表面和内表面的壳的芯，其中壳围绕芯，使得壳内表面基本上保形地驻留在芯外表面上，壳厚度在约100-400微米的范围内，剂型上的壳厚度的相对标准偏差小于约30％，壳包含小于约50％的可结晶糖，并且剂型基本上不含控制剂。在另一个实施方案中，剂型包括具有外表面和具有外表面和内表面的壳的芯，其中壳包围芯，剂量形式在40℃和75％相对湿度下暴露于60分钟时的吸湿性较小约为0.80％，壳厚度在约100-400微米的范围内，剂型上壳厚度的相对标准偏差小于约30％，剂型基本上不含电荷控制剂，而壳体基本上没有凸起的接缝。

8. 发明申请

WO2008039698A1 MULTI-CORE SOLID DOSAGE FORM COMPRISING A TRANSPARENT COATING BETWEEN SAID CORES 审中-公开
标题翻译：多核固体剂型，包含正确的皮肤之间的透明涂层
公开(公告)号：WO2008039698A1
公开(公告)日：2008-04-03
申请号：PCT/US2007/079148
申请日：2007-09-21
申请人： MCNEIL-PPC, INC. , LI, Shun, Por , NAEF, Hanspeter , BUNICK, Frank , LEE, Der, Yang
发明人： LI, Shun, Por , NAEF, Hanspeter , BUNICK, Frank , LEE, Der, Yang
IPC分类号： A61K9/40 , A61K9/42 , A61K9/44 , A61K9/20 , A61K9/26 , A61K9/28
CPC分类号： A61K9/2054 , A61K9/2072 , A61K9/2077 , A61K9/2853 , A61K9/2873 , A61K9/2893
摘要： The present invention is directed to a solid dosage form having at least two compressed portions and at least one light transmitting layer that is provided between said compressed portions. Each of said compressed portions having at least one surface area, a horizontal axis and a vertical axis. The light transmitting layer covers at least one surface of each compressed portions and is at least translucent along at least one axis of the compressed portions.
摘要翻译：本发明涉及一种具有至少两个压缩部分和设置在所述压缩部分之间的至少一个透光层的固体剂型。每个所述压缩部分具有至少一个表面积，水平轴线和垂直轴线。光透射层覆盖每个压缩部分的至少一个表面，并且沿着压缩部分的至少一个轴线至少是半透明的。

9. 发明申请

WO2006046954A1 BURST-RELEASE POLYMER COMPOSITION AND DOSAGE FORMS COMPRISING THE SAME 审中-公开
标题翻译： BURST-RELEASE聚合物组合物和包含其的剂型
公开(公告)号：WO2006046954A1
公开(公告)日：2006-05-04
申请号：PCT/US2004/035763
申请日：2004-10-26
申请人： MCNEIL-PPC, INC. , LI, Shun-Por , LEE, Der-Yang , BUNICK, Frank, J. , CHEN, Jen, Chi , SOWDEN, Harry, S.
发明人： LI, Shun-Por , LEE, Der-Yang , BUNICK, Frank, J. , CHEN, Jen, Chi , SOWDEN, Harry, S.
IPC分类号： A61K9/20
CPC分类号： A61K9/282 , A61K9/2013 , A61K9/205 , A61K9/2054 , A61K9/286 , A61K9/2866
摘要： A composition comprising a high molecular weight, water soluble polymer having a cloud point from about 20 to about 90° C and at least one carrageenan is provided. The composition may be used as a component of a pharmaceutical dosage form, such as the shell of a dosage form, to provide burst release of active ingredient contained therein.
摘要翻译：提供了包含高分子量水溶性聚合物的组合物，其具有约20至约90℃的浊点和至少一种卡拉胶。组合物可以用作药物剂型的组分，例如剂型的壳，以提供其中所含的活性成分的爆发释放。

10. 发明申请

WO2003026629A2 MODIFIED RELEASE DOSAGE FORMS 审中-公开
标题翻译：修改释放剂量表
公开(公告)号：WO2003026629A2
公开(公告)日：2003-04-03
申请号：PCT/US2002/031117
申请日：2002-09-28
申请人： MCNEIL-PPC, INC. , LEE, Der-Yang , LI, Shun-Por , SOWDEN, Harry, S. , THOMAS, Martin , WYNN, David
发明人： LEE, Der-Yang , LI, Shun-Por , SOWDEN, Harry, S. , THOMAS, Martin , WYNN, David
IPC分类号： A61K9/28
CPC分类号： A23G3/04 , A23G1/54 , A23G3/0029 , A23G3/368 , A23G3/54 , A23L29/30 , A61J3/005 , A61J3/06 , A61J3/10 , A61K9/0004 , A61K9/0056 , A61K9/2013 , A61K9/2018 , A61K9/2027 , A61K9/2031 , A61K9/2054 , A61K9/2068 , A61K9/2072 , A61K9/2081 , A61K9/209 , A61K9/2095 , A61K9/282 , A61K9/2826 , A61K9/284 , A61K9/286 , A61K9/2873 , A61K9/2886 , A61K9/2893 , A61K9/5084 , B30B11/08 , B30B11/34 , B30B15/302 , Y10T428/1352
摘要： A dosage form comprises: (a) at least one active ingredient: (b) a core having a first surface portion upon which resides a first coating and a second surface portion which is substantially free of the first coating; and (c) a shell which resides upon at least a portion of the second surface portion, wherein the shell comprises a different material from the first coating. In another embodiment, the dosage form comprises: (a) at least one active ingredient; (b)a core comprising a center portion having an exterior surface and an annular portion having an exterior surface and an interior surface, wherein the annular portion interior surface is in contact with at least a portion of the center portion exterior surface, and a coating resides on at least a portion of the annular portion exterior surface; and (c) a shell which resides upon at least a portion of the exterior surface of the center portion, wherein the shell comprises a different material than the impermeable coating. In another embodiment, the dosage form comprises: (a) at least one active ingredient; (b) a core having an outer surface and a cavity which extends at least partially through the core such that the core outer surface has at least a first opening therein; (c) a first coating which resides on at least a portion of the core outer surface, wherein the first shell portion comprises a different material from the first coating; and (d) a first shell portion which is adjacent to the first opening and covers at least the first opening.
摘要翻译：剂型包括：（a）至少一种活性成分：（b）具有第一表面部分的核心，其上存在第一涂层和基本上不含第一涂层的第二表面部分; 和（c）位于第二表面部分的至少一部分上的外壳，其中壳体包括与第一涂层不同的材料。在另一个实施方案中，剂型包含：（a）至少一种活性成分; （b）芯部，其包括具有外表面的中心部分和具有外表面和内表面的环形部分，其中所述环形部分内表面与所述中心部分外表面的至少一部分接触，位于环形部分外表面的至少一部分上; 和（c）驻留在中心部分的外表面的至少一部分上的壳体，其中壳体包括与不可渗透涂层不同的材料。在另一个实施方案中，剂型包含：（a）至少一种活性成分; （b）具有外表面和空腔的芯体，其至少部分地穿过所述芯部，使得所述芯部外表面至少具有第一开口; （c）驻留在所述芯外表面的至少一部分上的第一涂层，其中所述第一壳部分包括与所述第一涂层不同的材料; 和（d）与第一开口相邻并且至少覆盖第一开口的第一壳体部分。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式